Overview

This trial has been completed.

Condition prostate cancer patients who have brachytherapy seed implant
Treatment mri scan
Sponsor University Health Network, Toronto
Collaborator Princess Margaret Hospital, Canada
Start date October 2012
End date August 2016
Trial size 10 participants
Trial identifier NCT01878058, UHN REB 12-5302-CE

Summary

This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds. Researchers hope that using SWI will eliminate the need to use CT imaging to detect your implanted radioactive seeds.

This study will also see if the MRI seed detection is as effective as current standard practice of seed detection (routine MRI and CT imaging). This technique would be beneficial for brachytherapy without the need to fuse the MRI and CT images, as is done currently.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Arm
(Other)
Patients will receive an extra MRI scan in addition to their routine scan.
mri scan
Patient will receive an additional MRI scan in addition to their standard of care imaging

Primary Outcomes

Measure
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce registration errors
time frame: 6 months
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce planning time for the post-implant plan
time frame: 6 months
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will eliminate the CT scan of the patient.
time frame: 6 months

Secondary Outcomes

Measure
Compare the differences in MR seed identification using the MR pulse sequence vs. CT images.
time frame: 6 months

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: 1. At least 18 years old 2. Histologic diagnosis of adenocarcinoma of the prostate 3. No contraindications for Pelvic body MRI 4. Patients undergoing LDR brachytherapy at PMH and scheduled for post implant analysis with CT-MR (standard at PMH) 5. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Contraindication for Pelvic body MRI 2. Patient not willing/consenting for this study

Additional Information

Official title Identifying Prostate Brachytherapy Seeds Using MRI
Principal investigator Saibishkumar Elantholiparameswaran, MD
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University Health Network, Toronto.